Elevation Oncology
Elevation Oncology
ELEV
NASDAQ
0.50
USD
0.00%
About
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent.
Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 697.8K |
| Three Month Average Volume | 27.2M |
| High Low | |
| Fifty-Two Week High | 5.8299 USD |
| Fifty-Two Week Low | 0.363 USD |
| Fifty-Two Week High Date | 03 Apr 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 0.778 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -68.93% |
| Thirteen Week Relative Price Change | -81.92% |
| Twenty-Six Week Relative Price Change | -85.88% |
| Fifty-Two Week Relative Price Change | -18.73% |
| Year-to-Date Relative Price Change | 22.34% |
| Price Change | |
| One Day Price Change | 2.34% |
| Thirteen Week Price Change | -80.65% |
| Twenty-Six Week Price Change | -84.47% |
| Five Day Price Change | -3.81% |
| Fifty-Two Week Price Change | 1.83% |
| Year-to-Date Price Change | 44.88% |
| Month-to-Date Price Change | -70.42% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.29198 USD |
| Book Value Per Share (Most Recent Quarter) | 1.48054 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.29198 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.48054 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.82938 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.34117 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.83993 USD |
| Normalized (Last Fiscal Year) | -1.24376 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.34117 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.83993 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.34117 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.83993 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.95903 USD |
| Cash Per Share (Most Recent Quarter) | 2.02818 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.34003 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.82948 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.90576 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 51.65% |
| EPS Change (Trailing Twelve Months) | 76.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -79,933,000 |
| Net Debt (Last Fiscal Year) | -52,970,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 55 |
| Long Term Debt to Equity (Most Recent Quarter) | 38 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 21 |
| Current Ratio (Most Recent Quarter) | 41 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -56,180,000 |
| Free Cash Flow (Trailing Twelve Months) | -43,318,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -10 |
| Net Interest Coverage (Trailing Twelve Months) | -25 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 55 |
| Total Debt to Equity (Most Recent Quarter) | 38 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -49.88% |
| Return on Assets (Trailing Twelve Months) | -35.30% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -88.03% |
| Return on Equity (Trailing Twelve Months) | -51.87% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -55.94% |
| Return on Investment (Trailing Twelve Months) | -37.14% |
| Return on Investment (5 Year) | -99,999.99% |